112,024 research outputs found
Taralli S, Sollini M, Milella M, Perotti G, Filice A, Menga M, Versari A, Rufini V. (18)F-FDG and (68)Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study.
No full textBackground: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin tumor. Currently, 18F-fluorodeoxy-
glucose (18F-FDG) PET/CT is the functional imaging modality of choice. Few data are available on the use
of 68Ga-somatostatin analogs. The aim of our study was to evaluate and compare the diagnostic performance of
18F-FDG and 68Ga-somatostatin analog PET/CT in MCC patients.
Results: Fifteen patients (12 males, 3 females; median age 73 years; range 41–81 years) with histologically proven
MCC (4 with unknown primary lesion) who underwent both 18F-FDG and 68Ga-somatostatin analog PET/CT for
staging, re-staging, or treatment response assessment were retrospectively evaluated. Results of both studies
were qualitatively analyzed and compared on a patient- and lesion-based analysis, using histology or clinical/
radiological follow-up as reference standard for final diagnosis. According to final diagnosis, 8/15 patients had at
least one MCC lesion and 7/15 had no evidence of disease. On a patient-based analysis, 18F-FDG and 68Gasomatostatin
analogs correctly classified as positive 8/8 (100% sensitivity) patients and as negative 6/7 (85.7%
specificity) and 5/7 (71.4% specificity) patients, respectively, with no significant difference. On a lesion-based
analysis, 18F-FDG detected 67/75 lesions (89%) and 68Ga-somatostatin analogs 69/75 (92%), with no significant
difference. In four patients with unknown primary MCC, both tracers failed to identify the primary MCC site.
Conclusions: Our preliminary data suggest that 18F-FDG and 68Ga-somatostatin analog PET/CT provide good and
equivalent diagnostic performance, adding interesting insights into the complex MCC biology. However, these
results do not suggest that 18F-FDG PET/CT should be replaced by 68Ga-somatostatin receptor imaging, which
should be performed in addition, according to clinical indication, to the perspective of “personalized medicine.
Update on Management of Medullary Thyroid Carcinoma: Focus on Nuclear Medicine
No full textCurrently, there is a discrepancy among the available guidelines on the usefulness of nuclear medicine techniques in medullary thyroid cancer (MTC) diagnosis and treatment. Aim of this review is to provide an update on diagnostic and therapeutic nuclear medicine techniques in this setting. Evidence-based data clearly demonstrates the usefulness of PET/CT with different radiopharmaceuticals in recurrent MTC (in particular when serum calcitonin is higher than 150 pg/mL or calcitonin doubling time is shortened) and 18F-FDOPA should be the preferred PET radiopharmaceutical. If 18F-FDOPA PET/CT is negative or unavailable, 18F-FDG PET/CT or 68Ga-DOTA-peptides PET/CT could be performed for MTC restaging. There is currently insufficient evidence to recommend PET/CT with several radiopharmaceuticals for MTC staging. Clinical experience on PET/MRI with different radiopharmaceuticals in MTC is still limited. Several investigational nuclear medicine therapeutic options are currently under evaluation in metastatic MTC. More data are needed to evaluate the efficacy, toxicity, and role of these therapeutic options in the management of MTC patients
Role of 18F-FDG PET-CT in head and neck squamous cell carcinoma
No full textThe role of PET-CT imaging in head and neck squamous cell carcinoma during pre-treatment staging, radiotherapy planning, treatment response assessment and post-therapy follow-up is reviewed with focus on current evidence, controversial issues and future clinical applications. in staging, the role of 18F-FDg PET-CT is well recognized for detecting cervical nodal involvement as well as for exclusion of distant metastases and synchronous primary tumours. in the evaluation of treatment response, the high negative predictive value of 18F-FDg PET-CT performed at least 8 weeks from the end of radio-chemotherapy allows prevention of unnecessary diagnostic invasive procedures and neck dissection in many patients, with a significant impact on clinical outcome. on the other hand, in this setting, the low positive predictive value due to possible post-radiation inflammation findings requires special care before making a clinical decision. Controversial data are currently available on the role of PET imaging during the course of radio-chemotherapy. The prognostic role of 18F-FDg PET-CT imaging in head and neck squamous cell carcinoma is recently emerging, in addition to the utility of this technique in evaluation of the tumour volume for planning radiation therapy. Additionally, new PET radiopharmaceuticals could provide considerable information on specific tumour characteristics, thus overcoming the limitations of 18F-FDg
Role of 131I-labelled anti-CEA/CA 19-9 monoclonal antibodies in the diagnosis and follow-up of gastrointestinal tumors
No full textNot availabl
Iodine-123-MIBG imaging of neuroblastoma: Utility of SPECT and delayed imaging
No full textPossible incremental diagnostic benefits of SPECT and delayed planar imaging with [123I]MIBG in neuroblastoma have not yet been fully established.
Methods: Whole-body delayed planar [123I]MIBG imaging at 48 hr and SPECT imaging of the chest-abdomen or other suspected sites obtained at 24 hr were compared with routine planar imaging at 24 hr in 83 studies of 29 children with neuroblastoma. The sensitivity for each of the [123I]MIBG imaging methods was calculated on a study-by-study and on a lesion-by-lesion basis.
Results: Fifty-one planar imaging studies were performed in 20 patients with evidence of disease which was detected in 48 studies by 24-hr imaging (94.1% sensitivity) and in 44 studies by 48-hr imaging (86.3% sensitivity). On a lesion-by-lesion basis, sensitivity was 88.8% for the 24-hr scan, 86.7% for the 48-hr scan and 92.2% for a combination of the two (p = ns). Forty-three SPECT studies were performed in 20 patients with evidence of disease in the field of view of the SPECT camera. Disease was detected in 40 SPECT studies (93% sensitivity), in 38 planar scans at 24 hr (84.4% sensitivity) and in 37 planar scans at 48 hr (86.0% sensitivity). On a lesion-by-lesion basis, sensitivity was 83.6% for the 24-hr planar scan, 86.1% for the 48-hr planar scan, 88.2% for a combination of the two planar scans and 97.9% for SPECT (p < 0.001 compared with planar). The anatomic locations of tumors were clearer on SPECT in 15 studies.
Conclusion: Delayed 48-hr planar scanning may occasionally depict more lesions than 24-hr imaging, but it may also miss lesions with rapid washout. SPECT imaging significantly increases the number of lesions detected and better defines anatomic location of tumors
Impact of Cold Somatostatin Analog Administration on Somatostatin Receptor Imaging: A Systematic Review
No full textPurpose The interactions between the administration of cold somatostatin analogs (cSAs) and their radiolabeled counterpart remain unclear, and discontinuation before imaging is still advised as a precaution. The aim of this systematic review is to evaluate the consequences of cSA administration on tumoral and surrounding healthy organs' uptake at somatostatin receptor (SSTR) imaging with SPECT or PET. Methods After registration of the study on Prospero (CRD42022360260), an electronic search of PubMed and Scopus databases was performed. Inclusion criteria were as follows: human patients referred for SSTR imaging for oncological purposes; at least 1 examination performed either before cSA administration or after a long-enough withdrawal of cSA treatment; at least 1 examination was performed under cSA treatment. Included articles were independently appraised by 2 authors using the standardized protocol provided by the Quality Assessment of Diagnostic Accuracy Studies. Discrepancies were solved by consensus. Results A total of 12 articles were included, 4 using 111In-pentetreotide and 8 using 68Ga-DOTA peptides. Administration of cSAs consistently resulted in decreased spleen and liver uptake (6.9% to 80% for spleen, 10% to 60% for liver) and increased tumor-to-background or tumor-to-healthy organ ratios. After cSA treatment, tumor uptake alone was unchanged or moderately decreased. Similar results were noted whether patient was octreotide-naive. Conclusion Impairment in SSTR imaging quality after cSA administration has not been demonstrated. On the contrary, the administration of cSAs seems to improve the contrast between tumoral lesions and the surroundings
author-bios-SRD-19-0063.R1 – Supplemental material for The Network Structure of Police Misconduct
No full textSupplemental material, author-bios-SRD-19-0063.R1 for The Network Structure of Police Misconduct by George Wood, Daria Roithmayr and Andrew V. Papachristos in Socius</p
Integrazione dell'imaging radiologico con i dati della medicina nucleare: il miglioramento diagnostico nell'accoppiata morfologia e funzione
No full text--
- …
